Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Research

Prevalence and gender distribution of the metabolic syndrome

Author: Anthonia O Ogbera

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

Background

The Metabolic syndrome (MetS) is a cardiovascular risk factor of public health significance and of recent has become a topical issue. The prevalence of diabetes mellitus (DM) is on the increase and with this scenario, a possible increase in burden of DM which may be largely attributed to cardiovascular complications is expected. The objective of this report is to determine the prevalence of the MetS and compare gender characteristics in subjects with type 2 DM.

Methods

Subjects with type 2 DM were recruited from an urban hospital for the study. Clinical data was obtained by interviewing the patients and referring to their Case folders. The anthropometric indices and blood pressure measurements were documented. Laboratory parameters analysed for included total cholesterol, high density and low density cholesterol, triglyceride and glycosylated haemoglobin. Statistical analysis included usage of Student's t test and chi square.

Results

963 patients with type 2 DM aged between 35-85 years were recruited for the study. The main outcome measures included the prevalence of the metabolic syndrome and the gender differences of its components. The prevalence of the metabolic syndrome was 86%. The frequency of occurrence of the MetS was similar for men (83%) and women (86%) and increased with age in both sexes. The prevalence of MetS increased from 11% among participants aged 20 through 29 years to 89% in participants aged 70 through 79. In our patients with DM, the commonest occurring and least detected MetS defining parameters are central obesity and elevated triglyceride levels respectively. The components of the MetS that differed significantly in both sexes was HDL-C. The combination of the components of the MetS were comparable in both genders and 5.8% of the subjects with the MetS had all components of the MetS.

Conclusion

The prevalence of the MetS in type 2DM is high in both genders and increases with age thus posing a potential high cardiovascular risk in this group of patients. The modifiable risk factors for the MetS should be a focus point in the management of subjects with type 2 DM,
Appendix
Available only for authorised users
Literature
1.
go back to reference Deedwania PC, Gupta R: Management issues in the metabolic syndrome. J Assoc Physicians India. 2006, 54: 797-810.PubMed Deedwania PC, Gupta R: Management issues in the metabolic syndrome. J Assoc Physicians India. 2006, 54: 797-810.PubMed
2.
go back to reference Reaven G: Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular diseases. Circulation. 2002, 106: 286-288. 10.1161/01.CIR.0000019884.36724.D9.CrossRefPubMed Reaven G: Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular diseases. Circulation. 2002, 106: 286-288. 10.1161/01.CIR.0000019884.36724.D9.CrossRefPubMed
3.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet , Cleeman Z, Zimmet , James I, Donato Karen: Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet , Cleeman Z, Zimmet , James I, Donato Karen: Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
4.
go back to reference Vitale C, Marazzi G, Volterrani M, Aloisio A, Rosano G, Fini M: Metabolic syndrome. Minerva Med. 2006, 97 (3): 219-29.PubMed Vitale C, Marazzi G, Volterrani M, Aloisio A, Rosano G, Fini M: Metabolic syndrome. Minerva Med. 2006, 97 (3): 219-29.PubMed
5.
go back to reference Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older. Diabetes. 2003, 52 (5): 1210-1214. 10.2337/diabetes.52.5.1210.CrossRefPubMed Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older. Diabetes. 2003, 52 (5): 1210-1214. 10.2337/diabetes.52.5.1210.CrossRefPubMed
6.
go back to reference AlSaraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, Cockburn BN: Prevalence of the metabolic syndrome in patients diabetes mellitus. Ir J Med Sc. 2009, 178 (3): 309-313. 10.1007/s11845-009-0302-z.CrossRef AlSaraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, Cockburn BN: Prevalence of the metabolic syndrome in patients diabetes mellitus. Ir J Med Sc. 2009, 178 (3): 309-313. 10.1007/s11845-009-0302-z.CrossRef
7.
go back to reference Wahab KW, Sani M, Gbadamosi M, Yandutse M: Frequency and determinants of the metabolic syndrome in apparently healthy adult Nigerians. Trop Doct. 2008, 38: 224-226. 10.1258/td.2007.070335.CrossRefPubMed Wahab KW, Sani M, Gbadamosi M, Yandutse M: Frequency and determinants of the metabolic syndrome in apparently healthy adult Nigerians. Trop Doct. 2008, 38: 224-226. 10.1258/td.2007.070335.CrossRefPubMed
8.
go back to reference Isezuo SA, Ezunu E: Demographic and clinical correlates of metabolic syndrome in Native African type 2 diabetic patients. J Natl Med Assoc. 2005, 97 (4): 557-563.PubMedCentralPubMed Isezuo SA, Ezunu E: Demographic and clinical correlates of metabolic syndrome in Native African type 2 diabetic patients. J Natl Med Assoc. 2005, 97 (4): 557-563.PubMedCentralPubMed
9.
go back to reference Fezeu L, Balkau B, Kengne AP, Sobyngwi E, Mbanya JC: Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis. 2007, 193 (1): 70-76. 10.1016/j.atherosclerosis.2006.08.037.PubMedCentralCrossRefPubMed Fezeu L, Balkau B, Kengne AP, Sobyngwi E, Mbanya JC: Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis. 2007, 193 (1): 70-76. 10.1016/j.atherosclerosis.2006.08.037.PubMedCentralCrossRefPubMed
10.
go back to reference Ahonen T, Saltevo J, Laakso M, Kautiainen H, Kumpusalo E, Vanhala M: Gender Differences Relating to Metabolic Syndrome and Proinflammation in Finnish Subjects with Elevated Blood Pressure. Mediators of Inflammation. 2009, Ahonen T, Saltevo J, Laakso M, Kautiainen H, Kumpusalo E, Vanhala M: Gender Differences Relating to Metabolic Syndrome and Proinflammation in Finnish Subjects with Elevated Blood Pressure. Mediators of Inflammation. 2009,
11.
go back to reference He Y, Jiang B, Wang J: Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol. 2006, 47: 1588-94. 10.1016/j.jacc.2005.11.074.CrossRefPubMed He Y, Jiang B, Wang J: Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol. 2006, 47: 1588-94. 10.1016/j.jacc.2005.11.074.CrossRefPubMed
12.
go back to reference Ford ES, Giles WH, Dietz WH: (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287 (3): 356-359. 10.1001/jama.287.3.356.CrossRefPubMed Ford ES, Giles WH, Dietz WH: (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287 (3): 356-359. 10.1001/jama.287.3.356.CrossRefPubMed
13.
go back to reference Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A: Characterization of lipid parameters in diabetes mellitus - a Nigerian report. Int Arch Med. 2009, 20;2 (1): 19-10.1186/1755-7682-2-19.CrossRef Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A: Characterization of lipid parameters in diabetes mellitus - a Nigerian report. Int Arch Med. 2009, 20;2 (1): 19-10.1186/1755-7682-2-19.CrossRef
14.
go back to reference Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007, 18 (3): 263-70. 10.1097/MOL.0b013e32814a645f.CrossRefPubMed Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007, 18 (3): 263-70. 10.1097/MOL.0b013e32814a645f.CrossRefPubMed
15.
go back to reference Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH: "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Med Indones. 2009, 41 (1): 20-4.PubMed Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH: "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Med Indones. 2009, 41 (1): 20-4.PubMed
17.
go back to reference Kelliny C, William J, Riesen W, Paccaud F, Bovet P: Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovascular Diabetology. 2008, 7: 2-10.1186/1475-2840-7-27.CrossRef Kelliny C, William J, Riesen W, Paccaud F, Bovet P: Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovascular Diabetology. 2008, 7: 2-10.1186/1475-2840-7-27.CrossRef
18.
go back to reference Pirjo Ilanne-Parikka, Johan Eriksson, Jaana Lindström, Helena Hämäläinen, Sirkka Keinänen-Kiukaanniemi, Mauri Laakso: Prevalence of the Metabolic Syndrome and Its Components Findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004, 27 (9): 2135-2140. 10.2337/diacare.27.9.2135.CrossRef Pirjo Ilanne-Parikka, Johan Eriksson, Jaana Lindström, Helena Hämäläinen, Sirkka Keinänen-Kiukaanniemi, Mauri Laakso: Prevalence of the Metabolic Syndrome and Its Components Findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004, 27 (9): 2135-2140. 10.2337/diacare.27.9.2135.CrossRef
19.
go back to reference Campbell C, Nasir K, Sarwar A, Meneghelo R, Carvalho R, Blumenthal R: Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. The American Journal of Cardiology. 2009, 100 (5): 840-843. 10.1016/j.amjcard.2007.04.018.CrossRef Campbell C, Nasir K, Sarwar A, Meneghelo R, Carvalho R, Blumenthal R: Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. The American Journal of Cardiology. 2009, 100 (5): 840-843. 10.1016/j.amjcard.2007.04.018.CrossRef
20.
go back to reference Cameron Adrian J, Boyko Edward J, Sicree Richard A, Zimmet Paul Z, Söderberg Stefan, Alberti K, George MM, Tuomilehto Jaakko, Chitson Pierrot, Shaw Jonathan E: Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity. 2008, 16 (12): 2707-16. 10.1038/oby.2008.412.CrossRefPubMed Cameron Adrian J, Boyko Edward J, Sicree Richard A, Zimmet Paul Z, Söderberg Stefan, Alberti K, George MM, Tuomilehto Jaakko, Chitson Pierrot, Shaw Jonathan E: Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity. 2008, 16 (12): 2707-16. 10.1038/oby.2008.412.CrossRefPubMed
21.
go back to reference Brown LK: A Waist Is a Terrible Thing to Mind. Central Obesity, the Metabolic Syndrome, and Sleep Apnea Hypopnea Syndrome. Chest. 2002, 122 (3): 774-778. 10.1378/chest.122.3.774.CrossRefPubMed Brown LK: A Waist Is a Terrible Thing to Mind. Central Obesity, the Metabolic Syndrome, and Sleep Apnea Hypopnea Syndrome. Chest. 2002, 122 (3): 774-778. 10.1378/chest.122.3.774.CrossRefPubMed
22.
go back to reference Ahmed AM: Prevalence of Metabolic Syndrome among Patients with Type 2 Diabetes in Aden Governorate. MEFJN. 2008, 7 (6): Ahmed AM: Prevalence of Metabolic Syndrome among Patients with Type 2 Diabetes in Aden Governorate. MEFJN. 2008, 7 (6):
23.
go back to reference Campbell C, Nasir K, Sarwar A, Meneghelo R, Carvalho J, Blumenthal R, Santos R: Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. The American Journal of Cardiology. 2009, 100 (5): 840-843. 10.1016/j.amjcard.2007.04.018.CrossRef Campbell C, Nasir K, Sarwar A, Meneghelo R, Carvalho J, Blumenthal R, Santos R: Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. The American Journal of Cardiology. 2009, 100 (5): 840-843. 10.1016/j.amjcard.2007.04.018.CrossRef
Metadata
Title
Prevalence and gender distribution of the metabolic syndrome
Author
Anthonia O Ogbera
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-1

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.